Kan et al. [36] investigated the effects of alogliptin treatment on liver function and glucose metabolism in NAFLD patients with T2D, carrying different PNPLA3 rs738409 C > G genotypes. The gene discussed is PNPLA3; the disease is type 2 diabetes mellitus.